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Abstract
Thromboprophylaxis can reduce the incidence of postoperative thromboembolic events by two-
thirds. Traditionally, unfractionated heparin, low-molecular-weight heparins, vitamin K antagonists,
and mechanical methods have been used. Recently, thrombin and factor Xa (FXa) antagonists have
been introduced in clinical practice. Advantages are oral administration, potentially higher efficacy in
reducing thromboembolic events without increasing major bleeding, and no need for monitoring of
the anticoagulatory effect. So far these drugs have mainly been tested after total hip and knee
arthroplasties. However, data after most other orthopedic and surgical procedures are sparse. In
special populations – for example, patients with renal failure – these drugs have not been sufficiently
tested yet. Accordingly, the clinical use of these promising new drugs should be restricted to
situations where efficacy has been proven with clear evidence from controlled clinical trials.
Introduction and context
Perioperative thromboembolism
Without adequate prophylaxis against thromboembo-
lism, the incidence of objectively confirmed, hospital-
acquired deep vein thrombosis may be as high as
10-40% among general surgical patients and 40-60%
following major orthopaedic surgery [1,2]. The incidence
of potentially fatal thromboembolic events can be
reduced by two-thirds with mechanical and drug based
prophylaxis [1]; therefore, routine prophylaxis is estab-
lished clinical practice nowadays [2,3]. However, recent
data suggest that a substantial portion of events occur
after hospital discharge and after stopping routine
prophylaxis [4,5].
Traditional thromboembolic prophylaxis
Traditional thromboembolic prophylaxis was mainly
based on the administration of unfractionated heparin,
low-molecular-weight heparins (LMWHs), vitamin K
antagonists, and mechanical methods [6]. Vitamin K
antagonists block biosynthesis of coagulation factors II
(prothrombin), VII, IX, and X. The main disadvantages
are the need for close monitoring and the risk of
interactions with ingested food and other drugs. Unfrac-
tionated heparin and LMWHs modulate coagulation by
enhancing the activity of antithrombin. Unfractionated
heparin inhibits FXa and thrombin activity (along with
coagulation factors); in contrast, LMWHs predominantly
inhibit FXa (Figure 1) [7]. Disadvantages of the heparins
include the need for monitoring when used in higher
doses, the risk of heparin-induced thrombocytopenia,
and the need for parenteral application, which can be
a challenge in outpatient settings. An advantage of
unfractionated heparin is the reversibility of the antic-
oagulatory effect by protamin administration.
Properties of an ideal anticoagulant are oral administra-
tion, rapid onset of action, no increased risk of bleeding,
predictable pharmacokinetics and pharmacodynamics,
fixed-dose administration, a wide therapeutic window,
and no need for monitoring [7]. The development of
new antithrombotic drugs aims to meet these require-
ments and has focussed mainly on FXa and thrombin
(Figure 1).
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Factor X inhibitors
The pentasaccharide fondaparinux indirectly inhibits
FXa by activating antithrombin. Fondaparinux has
been widely investigated and is recommended for
thromboembolic prophylaxis in patients undergoing
major orthopedic surgery [2,3]. The evidence for a
beneficial effect of fondaparinux is even higher than
that for LMWHs (i.e., enoxaparin 40 mg once daily) for
patients who have had surgery for hip fracture [2].
Fondaparinux is administered by one subcutaneous
injection per day. The slow elimination (half life of 13-
21 hours), and the irreversibility of FXa inhibition are
shortcomings in situations when surgical revision is
required. The drug is eliminated unmetabolised by the
kidneys. It should be used cautiously in patients with
renal failure. Monitoring of the effect of fondaparinux in
clinical practice is challenging because the anti-FXa tests
developed for LMWHs are inappropriate and a drug-
specific anti-FXa test has to be used.
Rivaroxaban is a selective direct FXa inhibitor that is
administered orally. Several studies have demonstrated
the efficacy of the drug for prevention of thromboem-
bolism after hip and knee arthroplasties. Compared with
the LMWH enoxaparin, rivaroxaban significantly
reduced the incidence of venous thromboembolism by
around a half without evidence for an increased risk of
major bleeding [8-13]. In hip and knee arthroplasty
patients, rivaroxaban is started after surgery and con-
tinued for up to 4 weeks. Following oral administration,
the drug is absorbed rapidly and maximal inhibition of
FXa is observed after 2-3 hours [14]. Several dose-finding
studies have been performed. However, the recently
published large trials in patients after hip and knee
arthroplasties all used a fixed dose of 10 mg rivoroxaban
given once daily [9,11-13]. It is important to notice that
patients with renal failure (creatinine clearance <30 mL/
minute) have been excluded from the studies and that
the use of the drug in these patients should be considered
as contraindicated.
Rivaroxaban prolongs classical coagulation tests, such as
prothrombin time and activated partial thromboplastin
time [14]. The latter has been suggested for monitoring
of the antithrombotic effect of rivaroxaban. However, its
clinical usefulness in this setting is unproven, and so far
no other tests are available.
Apixaban, otamixaban, betrixaban, idraparinux, and
edoxaban are examples of other FXa inhibitors currently
under clinical investigation [15-18]. Oral apixaban
(2.5 mg twice daily) was equally efficient or even
superior to enoxaparin after knee and hip arthroplasties
but caused less bleeding [15,19]. In contrast, studies with
idraparinux produced evidence for increased incidences
of bleeding [18,20].
Thrombin inhibitors
The direct thrombin inhibitors are small molecules that
bind directly to the active catalytic site of thrombin.
Hirudin was the first direct thrombin inhibitor intro-
duced in clinical practice. It is administered parenterally.
Along with other thrombin inhibitors (lepirudin, arga-
troban, and bivalirudin), hirudin is mainly used in
patients with heparin-induced thrombocytopenia [21].
Ximelagatran is an orally acting thrombin inhibitor with
promising results in the prevention of thromboembolic
events. However, it was withdrawn from the market
because of hepatotoxic effects.
Dabigatran is a newer orally administered thrombin
inhibitor. The prodrug dabigatran etexilate is rapidly
absorbed and converted to the active form, dabigatran.
The terminal half-life is 14-17 hours [7]. Dabigatran was
as effective as LMWHs (enoxaparin 40 mg once daily) in
the prevention of thromboembolic events after total hip
arthroplasty with a similar safety profile [22,23]. In
patients after knee arthroplasty, dabigatran showed
inferior efficacy compared with enoxaparine 30 mg
twice a day [24]. Moreover, patients with severe renal
failure have been excluded from the study populations.
Bivalirudin is another direct thrombin inhibitor. The drug
is administered intravenously. Promising results have
been obtained in patients with acute coronary syndromes
[25]. However, the drug has not been investigated for
prophylaxis of thromboembolic events after surgery.
Figure 1. Simplified coagulation cascade and the targets of
heparins and thrombin and factor Xa inhibitors
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The new anticoagulants seem to have many advantages
over the traditionally used LMWHs. Oral administration
and potentially higher efficacy in reducing thromboem-
bolic events without increase in major bleeding are two
of them. As the duration of antithrombotic treatment
after major surgery is under debate and might be
prolonged based on recent data, oral administration is
an important advantage.
If efficacy and freedom from serious adverse events,
including major bleeding, are confirmed in clinical
practice, these drugs will replace traditionally used
medication in many situations. So far, however, their
use should be restricted to situations where their efficacy
has been proven with clear evidence from controlled
clinical trials. It is important to note that data on the use
of the newer drugs in patients with renal failure are
lacking. Another unresolved problem is the monitoring
of the effect of the drugs. Monitoring is considered
unnecessary in most clinical settings but could be
important if major bleeding occurs, in patients who
have taken higher than recommended doses, or in cases
of severe renal or hepatic failure. In addition, reversal of
these drugs is difficult as there are no antidotes available.
It is crucial that surgeons, anesthetists, and all other
physicians involved in the perioperative care of surgical
patients are aware of the properties of the new drugs and
make sure that their use is correctly incorporated in
clinical routines.
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